BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30133757)

  • 1. Tumor heterogeneity, aggressiveness, and immune cell composition in a novel syngeneic PSA-targeted Pten knockout mouse prostate cancer (MuCaP) model.
    van Duijn PW; Marques RB; Ziel-van der Made ACJ; van Zoggel HJAA; Aghai A; Berrevoets C; Debets R; Jenster G; Trapman J; van Weerden WM
    Prostate; 2018 Sep; 78(13):1013-1023. PubMed ID: 30133757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timp3 loss accelerates tumour invasion and increases prostate inflammation in a mouse model of prostate cancer.
    Adissu HA; McKerlie C; Di Grappa M; Waterhouse P; Xu Q; Fang H; Khokha R; Wood GA
    Prostate; 2015 Dec; 75(16):1831-43. PubMed ID: 26332574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors.
    Kwak MK; Johnson DT; Zhu C; Lee SH; Ye DW; Luong R; Sun Z
    PLoS One; 2013; 8(1):e53476. PubMed ID: 23308230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.
    Ma X; Ziel-van der Made AC; Autar B; van der Korput HA; Vermeij M; van Duijn P; Cleutjens KB; de Krijger R; Krimpenfort P; Berns A; van der Kwast TH; Trapman J
    Cancer Res; 2005 Jul; 65(13):5730-9. PubMed ID: 15994948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Heterogeneous Prostate Tumors in Targeted Pten Knockout Mice.
    Korsten H; Ziel-van der Made AC; van Weerden WM; van der Kwast T; Trapman J; Van Duijn PW
    PLoS One; 2016; 11(1):e0147500. PubMed ID: 26807730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
    Tan M; Xu J; Siddiqui J; Feng F; Sun Y
    Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic and transcriptomic profiling of Pten gene-knockout mouse model of prostate cancer.
    Zhang J; Kim S; Li L; Kemp CJ; Jiang C; Lü J
    Prostate; 2020 May; 80(7):588-605. PubMed ID: 32162714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a Pten knockout mouse prostate cancer model.
    Korsten H; Ziel-van der Made A; Ma X; van der Kwast T; Trapman J
    PLoS One; 2009 May; 4(5):e5662. PubMed ID: 19461893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma.
    Ratnacaram CK; Teletin M; Jiang M; Meng X; Chambon P; Metzger D
    Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2521-6. PubMed ID: 18268330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
    Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.
    Yamamoto Y; De Velasco MA; Kura Y; Nozawa M; Hatanaka Y; Oki T; Ozeki T; Shimizu N; Minami T; Yoshimura K; Yoshikawa K; Nishio K; Uemura H
    J Transl Med; 2015 May; 13():150. PubMed ID: 25953027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An in vitro system to characterize prostate cancer progression identified signaling required for self-renewal.
    Salah M; Nishimoto Y; Kohno S; Kondoh A; Kitajima S; Muranaka H; Nishiuchi T; Ibrahim A; Yoshida A; Takahashi C
    Mol Carcinog; 2016 Dec; 55(12):1974-1989. PubMed ID: 26621780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylseleninic Acid Superactivates p53-Senescence Cancer Progression Barrier in Prostate Lesions of Pten-Knockout Mouse.
    Wang L; Guo X; Wang J; Jiang C; Bosland MC; Lü J; Deng Y
    Cancer Prev Res (Phila); 2016 Jan; 9(1):35-42. PubMed ID: 26511486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aqueous metabolome of tissue-specific conditional Pten-knockout mouse prostate cancer and TRAMP neuroendocrine carcinoma.
    Kim S; Li L; Zhang J; Jiang C; Lü J
    Prostate; 2022 Jan; 82(1):154-166. PubMed ID: 34662447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer.
    Allott EH; Masko EM; Freedland AR; Macias E; Pelton K; Solomon KR; Mostaghel EA; Thomas GV; Pizzo SV; Freeman MR; Freedland SJ
    Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):196-203. PubMed ID: 29795142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.
    Riabov V; Tretyakova I; Alexander RB; Pushko P; Klyushnenkova EN
    Vaccine; 2015 Oct; 33(41):5386-5395. PubMed ID: 26319744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model.
    Kwon OJ; Zhang L; Wang J; Su Q; Feng Q; Zhang XH; Mani SA; Paulter R; Creighton CJ; Ittmann MM; Xin L
    J Clin Invest; 2016 Jul; 126(7):2626-41. PubMed ID: 27294523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel syngeneic mouse mammary carcinoma cell lines from aggressive ErbB2/Neu-overexpressing/PTEN-deficient tumors.
    Wang Q; Ding H; Wang H; Li P; Liu B; Zhang K
    Oncol Rep; 2015 Jan; 33(1):179-84. PubMed ID: 25354531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased T-cell Infiltration Elicited by
    Loveridge CJ; Mui EJ; Patel R; Tan EH; Ahmad I; Welsh M; Galbraith J; Hedley A; Nixon C; Blyth K; Sansom O; Leung HY
    Cancer Res; 2017 Jun; 77(12):3158-3168. PubMed ID: 28515147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.
    De Velasco MA; Kura Y; Yoshikawa K; Nishio K; Davies BR; Uemura H
    Oncotarget; 2016 Mar; 7(13):15959-76. PubMed ID: 26910118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.